Compare iShares MSCI Canada (TSX) (EWC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Novavax Inc — how do they compare? iShares MSCI Canada (TSX) trades at $58.91 (market cap $6.99B), while Novavax Inc trades at $12.64 (market cap $1.82B). The key difference: iShares MSCI Canada (TSX) is far larger — about 3.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, iShares MSCI Canada (TSX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 56 Days and Novavax Inc for 59 Days on average.
| EWC | NVAX | |
|---|---|---|
Market Cap | $6.99B | $1.82B |
Volume | 1,625,847 | 6,198,505 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $12.56 |
52-Week Low | $49.72 | $6.22 |
Typical Hold Time | 56 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $57.94, down 2.1% today amid a bearish technical signal with moving averages indicating selling pressure. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights trade tensions between the U.S. and Canada, with potential impacts on cross-border economic activity and market sentiment.
The outlook is clouded by geopolitical risks from U.S.-Canada trade disputes, which could pressure performance. Investment opportunities hinge on resolution of trade frictions and improved economic data. Key risks include prolonged trade uncertainty and volatility from political developments.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
